BindingDB BDBM50363397 CHEMBL1946170::REGORAFENIB::US10183928, Regorafenib::US10202365, Compound Regorafenib::US10227329, Compound Regorafenib::US10464902, Regorafenib::US10584114, Compound Regorafenib::US10774070, Compound Regorafenib::US11279688, Compound Regorafenib

BDBM50363397 CHEMBL1946170::REGORAFENIB::US10183928, Regorafenib::US10202365, Compound Regorafenib::US10227329, Compound Regorafenib::US10464902, Regorafenib::US10584114, Compound Regorafenib::US10774070, Compound Regorafenib::US11279688, Compound Regorafenib

SMILES CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1

InChI Key InChIKey=FNHKPVJBJVTLMP-UHFFFAOYSA-N

Data 1 KI 46 IC50 1 Kd 1 EC50

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 50363397

Vascular endothelial growth factor receptor 2(Homo sapiens (Human))
Ontogenesis

US Patent

BDBM50363397(CHEMBL1946170 | REGORAFENIB | US10183928, Regorafe...)

Ki: 4.20nMAssay Description:Compounds 2-4 and cabozantinib were each tested for binding of c-Met, VEGFR2, TIE2 and the control compound, staurosporine. Specifically, each compou...More data for this Ligand-Target Pair

PDB MMDB NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar

Purchase ChEBI
CHEMBL DrugBank MCE
PC cid PC sid Patents Similars

Details US Patent DrugBank

Filter my 49 hits

Targets 17▿
- Proto-oncogene tyrosine-protein kinase receptor Ret 8
- Vascular endothelial growth factor receptor 2 7
- Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] 6
- Serine/threonine-protein kinase B-raf 5
- Mast/stem cell growth factor receptor Kit 3
- Proto-oncogene tyrosine-protein kinase receptor Ret [V804M] 3
- Vascular endothelial growth factor receptor 1 3
- Angiopoietin-1 receptor 2
- RAF proto-oncogene serine/threonine-protein kinase 2
- Fibroblast growth factor receptor 1 2
- Vascular endothelial growth factor receptor 3 2
- Receptor-type tyrosine-protein kinase FLT3 1
- Ephrin type-A receptor 2 [596-900] 1
- Bifunctional epoxide hydrolase 2 1
- Platelet-derived growth factor receptor beta 1
- Broad substrate specificity ATP-binding cassette transporter ABCG2 1
- Glycine receptor subunit alpha-1 1
- ...
Publications 20▿
- J Med Chem 64: 11747-11773 (2021) 10
- Eur J Med Chem 179: 707-722 (2019) 10
- US Patent US10774070 (2020) 3
- US Patent US10227329 (2019) 3
- US Patent US10202365 (2019) 3
- US Patent US11279688 (2022) 2
- J Med Chem 62: 11135-11150 (2019) 2
- US Patent US10183928 (2019) 2
- Eur J Med Chem 179: 916-935 (2019) 2
- US Patent US10584114 (2020) 2
- Eur J Med Chem 234: (2022) 1
- J Med Chem 60: 8801-8815 (2017) 1
- Bioorg Med Chem Lett 22: 789-92 (2012) 1
- ACS Chem Biol 11: 3400-3411 (2016) 1
- Bioorg Med Chem Lett 23: 3732-7 (2013) 1
- US Patent US10464902 (2019) 1
- J Med Chem 65: 893-921 (2022) 1
- Eur J Med Chem 168: 315-329 (2019) 1
- Eur J Med Chem 237: (2022) 1
- J Med Chem 58: 2958-66 (2015) 1
Institutions 15▿
- Blueprint Medicines 15
- University Of Arkansas For Medical Sciences 10
- National Research Centre 10
- Fuzhou University 2
- National Health Research Institutes 2
- Csir-Indian Institute Of Integrative Medicine 1
- Ontogenesis 1
- Technical University of Munich 1
- Mansoura University 1
- Tu Dortmund University 1
- The Institute Of Cancer Research 1
- University Of Gothenburg 1
- University Of Pittsburgh 1
- Federal University Of Parana 1
- University Of California 1
Affinity: 0.5 to 3.0E+3 nM▿
- Ki 1
- IC50 46
- Kd 1
- EC50 1
- Affinity ≤ nM
Xtal structures: 0
Docked structures: 0
Catalog Cmpds: 1